key: cord-1002944-ueaoipgl
authors: Shen, Liang; Niu, Junwei; Wang, Chunhua; Huang, Baoying; Wang, Wenling; Zhu, Na; Deng, Yao; Wang, Huijuan; Ye, Fei; Cen, Shan; Tan, Wenjie
title: High-Throughput Screening and Identification of Potent Broad-Spectrum Inhibitors of Coronaviruses
date: 2019-03-27
journal: Journal of Virology
DOI: 10.1128/jvi.00023-19
sha: 8eacedf54b52b89b270a2e148459b6d0ca6898ee
doc_id: 1002944
cord_uid: ueaoipgl

Coronaviruses (CoVs) act as cross-species viruses and have the potential to spread rapidly into new host species and cause epidemic diseases. Despite the severe public health threat of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome CoV (MERS-CoV), there are currently no drugs available for their treatment; therefore, broad-spectrum inhibitors of emerging and endemic CoVs are urgently needed. To search for effective inhibitory agents, we performed high-throughput screening (HTS) of a 2,000-compound library of approved drugs and pharmacologically active compounds using the established genetically engineered human CoV OC43 (HCoV-OC43) strain expressing Renilla luciferase (rOC43-ns2Del-Rluc) and validated the inhibitors using multiple genetically distinct CoVs in vitro. We screened 56 hits from the HTS data and validated 36 compounds in vitro using wild-type HCoV-OC43. Furthermore, we identified seven compounds (lycorine, emetine, monensin sodium, mycophenolate mofetil, mycophenolic acid, phenazopyridine, and pyrvinium pamoate) as broad-spectrum inhibitors according to their strong inhibition of replication by four CoVs in vitro at low-micromolar concentrations. Additionally, we found that emetine blocked MERS-CoV entry according to pseudovirus entry assays and that lycorine protected BALB/c mice against HCoV-OC43-induced lethality by decreasing viral load in the central nervous system. This represents the first demonstration of in vivo real-time bioluminescence imaging to monitor the effect of lycorine on the spread and distribution of HCoV-OC43 in a mouse model. These results offer critical information supporting the development of an effective therapeutic strategy against CoV infection. IMPORTANCE Currently, there is no approved therapy to treat coronavirus infection; therefore, broad-spectrum inhibitors of emerging and endemic CoVs are needed. Based on our high-throughput screening assay using a compound library, we identified seven compounds with broad-spectrum efficacy against the replication of four CoVs in vitro. Additionally, one compound (lycorine) was found to protect BALB/c mice against HCoV-OC43-induced lethality by decreasing viral load in the central nervous system. This inhibitor might offer promising therapeutic possibilities for combatting novel CoV infections in the future.

ited the replication of HCoV-NL63 (EC 50 Ͻ 5 M), which is an alpha-CoV that usually causes the common cold, whereas 13 and 12 compounds inhibited MERS-CoV and MHV-A59 replication (EC 50 Ͻ 5 M), respectively (Table 1) . Moreover, we newly identified nine compounds (phenazopyridine, lycorine, pyrvinium pamoate, monensin sodium, cetylpyridinium chloride, oligomycin, loperamide, harmine, and conessine) as exhibiting antiviral activity against severe CoV (MERS-CoV) ( Table 1) . Interestingly, the following seven compounds inhibited the replication of all CoVs with EC 50 values of Ͻ5 M: lycorine, emetine, phenazopyridine, mycophenolic acid, mycophenolate mofetil, pyrvinium pamoate, and monensin sodium ( Table 1 , compounds indicated in bold).

These seven broad-spectrum inhibitors suppressed the replication of all CoVs in a dose-dependent manner and with low EC 50 values (Fig. 2) . Lycorine, an active alkaloid from the common folk medicine Lycoris radiata (Amaryllidaceae) has been investigated for its multifunctional biological effects, including anticancer, antimalarial, antiviral, antibacterial, and anti-inflammatory activities (19) (20) (21) (22) (23) . Lycorine showed potent anti-CoV activity, with EC 50 values ranging from 0.15 M to 1.63 M. Moreover, the selective index (SI) of lycorine for HCoV-OC43 was calculated at 29.13, indicating its potent (Fig. 2E) . Mycophenolate mofetil, a derivative of mycophenolic acid, showed an antiviral effect on the four CoVs similar to that of mycophenolic acid, suggesting that the two drugs might harbor similar core structures and antiviral mechanisms ( Fig. 2C and E) . Moreover, phenazopyridine, a widely used urinary analgesic, also displayed strong broad-spectrum anti-CoV activity for the first time, especially against MHV-A59 (EC 50 of 0.77 M and SI of Ͼ25.97) (Fig. 2D ). Pyrvinium pamoate is an FDA-approved anthelminthic drug and a potent inhibitor of WNT signaling, suggested to occur through direct activation of protein kinase CK1␣ (24) . Pyrvinium pamoate inhibited the replication of all CoVs and displayed low toxicity (50% cytotoxic concentration [CC 50 ], Ͼ19 M) (Fig. 2F ). Finally, monensin sodium, previously shown to inhibit the formation of gamma-CoV infectious bronchitis virus (IBV), inhibited all CoVs at low EC 50 values and displayed low toxicity (Fig. 2G ). Although the specific antiviral mechanisms of these seven inhibitors against CoVs are unknown, they showed potential as new antivirals for the treatment of infections caused by a range of CoVs. Validation of anti-CoV activity. We verified the antiviral activity of the seven inhibitors against HCoV-OC43 by indirect immunofluorescence assay (IFA) and Western blot analysis. As shown in Fig. 3A , all seven inhibitors significantly suppressed HCoV-OC43 replication, compared with that of the control (dimethyl sulfoxide [DMSO]), and with a Ͼ90% inhibitory effect for most compounds, except for monensin sodium. Additionally, we observed inhibitory activity when the cells were treated with the inhibitors after viral infection, resulting in significantly reduced levels of HCoV-OC43 nucleocapsid protein (Fig. 3B ). Although the inhibitory effect of mycophenolic acid differed according to IFA and Western blot results, the seven inhibitors clearly suppressed HCoV-OC43 replication.

Emetine inhibited MERS-CoV entry. Viral entry is an essential step of the viral life cycle and is thus an attractive target for therapy. Inhibition of this step can block viral propagation at an early stage of infection, thereby minimizing the chance for the virus to evolve and acquire drug resistance. Therefore, we tested the effect of the seven screened inhibitors on CoV entry using a pseudotype virus with a human immunodeficiency virus type 1 (HIV-1) backbone but expressing the spike protein of MERS-CoV in order to generate dose-response curves. Measurement of the inhibition percentage showed that only emetine was an entry inhibitor that blocked MERS-CoV S-mediated infection, with luciferase activity reduced 50-fold compared with that of the control and an EC 50 value of 0.16 M (Fig. 4) .

HCoV-OC43 infects neurons and causes encephalitis in mice, with this model previously used for anti-CoV drug evaluation (25) . Moreover, this model was convenient based on the lack of need for three biological facilities, in contrast to experiments involving SARS-CoV or MERS-CoV. Therefore, we used this model to evaluate the in vivo antiviral activity of the seven inhibitors. Intracerebral or intranasal inoculation of HCoV-OC43 results in acute-onset severe neurological illness and causes death, with high levels of viral replication in the brain (titer, Ͼ10 6 50% tissue culture infective doses [TCID 50 ]/ml) at 3 to 5 days after infection (26) (27) (28) (29) . Briefly, female BALB/c mice (12 days old) were inoculated via the intranasal route with 100 TCID 50 of HCoV-OC43-WT and treated with the seven inhibitors for 14 days, and their survival was monitored for up to 20 days. The inhibitor doses and regimens were selected based on acute-toxicity assessments. Emetine was used at 5 mg/kg, and chloroquine was used as the positive control, which showed antiviral activity at 30 mg/kg. All mice in the phosphate-buffered saline (PBS)-DMSO-treated group died within 6 days after HCoV-OC43-WT challenge (Fig. 5A ). In contrast, 83.3% of mice in the lycorine-treated group were still alive at 20 days postinoculation (P Ͻ 0.001), similar to the survival rate of the chloroquine-treated group (Fig. 5A) . Additionally, viral loads in the brain and spinal cord were under the limit of detection in the lycorine-treated group (Fig. 5B) , and immunohistochemistry (IHC) of mouse brain coronal sections showed that HCoV-OC43 nucleocapsid protein was present only in the PBS-DMSO-treated group, not in the lycorine-treated group (Fig. 5C) .

Lycorine blocked the spread of rOC43-ns2Del-Rluc in the mouse brain. To more closely monitor the effect of lycorine on the spread and replication of HCoV-OC43 in the mouse central nervous system in real time, we used bioluminescence imaging (BLI) based on its important advantages of an intrinsically low background signal and very high sensitivity for monitoring light emission in vivo. As expected, PBS-DMSO-treated mice showed gradually increasing signal intensity postinoculation, whereas no signal was detected in the brains of lycorine-treated mice (Fig. 6A) . These observations were confirmed by the ϳ2 ϫ 10 5 -fold-higher Rluc activity in the PBS-DMSO-treated mice than in the lycorine-treated mice. Therefore, lycorine showed promise as an anti-CoV agent (Fig. 6B ).

The SARS epidemic in 2003 and the ongoing MERS-CoV outbreak highlight the inadequacy of available treatments for life-threatening zoonotic CoV infections in humans. Indeed, no specific antiviral agent or vaccine is currently available for human or zoonotic CoV infections, despite the extensive research efforts triggered by the SARS outbreak (30) (31) (32) . Several FDA-approved drugs (ritonavir, lopinavir, nelfinavir, mycophenolic acid, and ribavirin) inhibit the entry and/or replication of MERS-CoV, SARS-CoV, or other human CoVs in multiple cell lines; however, their antiviral efficacy in vivo remains unknown (16, (32) (33) (34) (35) (36) (37) . To date, few small molecules have demonstrated anti-CoV activity in animal models of CoV infection (17, 38, 39) , and most of the available anti-CoV drugs that target structural proteins might not be effective against other CoVs. For example, the human monoclonal antibodies and antiviral peptides that block virus-host cell binding typically have a limited breadth of protection due to the antigenic diversity in the CoV spike glycoprotein (40, 41) . It is worth mentioning that combining antiviral peptides with beta interferon (IFN-␤) (40) or combination therapy with different humanized or human monoclonal antibodies targeting non-crossresistant epitopes (42) can enhance antiviral therapeutic effects. There are also several reports of the enhanced therapeutic effects of combinations of other antiviral agents for the treatment of MERS-CoV. These results indicate that the combined use of different antiviral agents might be synergistic in their treatment of CoV infection.

Here, we identified seven potent broad-spectrum anti-CoV agents, among which lycorine was confirmed as showing strong anti-CoV activity in vivo. Our results suggest that FDA-approved drugs can be used for the prophylaxis of severe or lethal CoV infections, thereby greatly facilitating the rapid and rational development of anti-CoV agents with desirable pharmacokinetic and biodistribution properties.

The criteria for the inhibition rate associated with the signals in the antiviral HTS assay ranged from ϳ30% to ϳ90% according to different references, with more primary hits but fewer efficacy hits screened when the inhibition rate was set to the lower threshold. In our experiment, we focused on screening hits with higher potency and, therefore, so established the inhibition threshold at 70%. Furthermore, we identified several effective hits with a high degree of cytotoxicity under 10 M in our primary screening, which was why the cytotoxicity value was set to 80%. Finally, we identified 36 compounds exhibiting anti-HCoV-OC43 activity from a library of compounds, two of which (chloroquine and loperamide) were previously reported as exhibiting broadspectrum anti-CoV activity. Nine compounds (phenazopyridine, lycorine, pyrvinium pamoate, monensin sodium, cetylpyridinium chloride, oligomycin, loperamide, harmine, and conessine) have not previously been demonstrated as exhibiting antiviral activity against MERS-CoV, thereby offering new therapeutic possibilities for this severe CoV. Furthermore, seven compounds (lycorine, emetine, monensin sodium, mycophenolate mofetil, mycophenolic acid, phenazopyridine, and pyrvinium pamoate) showed inhib- mice Ͼ20 days after intranasal inoculation of HCoV-OC43, followed by treatment with the indicated inhibitors (n ϭ 6/group). Inhibitor doses and regimens were selected based on their acute toxicity (emetine was used at 5 mg/kg, chloroquine was used at 30 mg/kg, and the other inhibitors were used at 15 mg/kg). (B) Viral loads in the mouse brain and spinal cord treated with lycorine. Twelve-day-old female BALB/c mice were inoculated via the intranasal route with 100 TCID 50 HCoV-OC43-WT and treated with lycorine or DMSO control for 3 days. At 72 h postinfection, viral loads in the mouse brain and spinal cord were determined by qRT-PCR. Data represent the mean Ϯ standard deviation (error bars) of the results of three independent experiments. (C) IHC analyses of brain tissue from mice treated with lycorine. Twelve-day-old female BALB/c mice were inoculated via the intranasal route with 100 TCID 50 HCoV-OC43-WT and treated with lycorine or DMSO control for 3 days. Mouse brain coronal sections were stained for HCoV-OC43 N (green) and nuclei (blue). itory activity against multiple genetically distinct CoVs in vitro at low-micromolar concentrations (EC 50 values ranging from 0.12 to 3.81 M). Among these, lycorine is an alkaloid isolated from Amaryllidaceae plants and reportedly exhibits anticancer, antiplasmodial, antitrypanosomal, anti-inflammatory, analgesic, and emetic activities (43) (44) (45) . Lycorine inhibits the replication of poliomyelitis virus, herpes simplex virus 1, Bunyamwera virus, West Nile virus, dengue virus, and SARS-CoV in vitro, although the mechanism remains to be elucidated (46) (47) (48) (49) . Liu et al. (50) demonstrated the ability of lycorine to reduce the mortality of human enterovirus 71-infected mice by inhibiting viral replication. Furthermore, Guo et al. (51) evaluated a total of 32 lycorine derivatives, demonstrating that 1-acetyllycorine suppressed enterovirus 71 and hepatitis C virus replication in various cells. Moreover, drug resistance analysis revealed that 1-acetyllycorine targeted a phenylalanine (F76) in the viral proteases. Lycorine also exhibits strong activities against influenza A virus H5H1 in vitro and delays the export of nucleoprotein from the nucleus to the cytoplasm during replication (52) . However, the potential mechanism of lycorine against CoVs requires further exploration, and its potential selection for drug-resistant strains must be assessed. We found no reports concerning whether its use in combination enhances the antiviral efficacy of lycorine. Additionally, emetine is a drug used mainly as both an antiprotozoal and an emetic (53) , with a number of groups recently reporting new antiviral roles for emetine. Emetine is reportedly a potent inhibitor that suppresses the replication of several RNA viruses (dengue virus and HIV) without generating drug-resistant variant viruses (54) (55) (56) . We noted that emetine inhibits human cytomegalovirus (HCMV) replication by disrupting the HCMV-induced interaction between p53 and the E3-ubiquitin ligase MDM2 (57). Moreover, a recent study revealed emetine as an inhibitory modulator of rabies virus axonal transport via a mechanism independent of protein synthesis inhibition (58) . Furthermore, Yang et al. (59) demonstrated that emetine inhibits Zika virus (ZIKV) replication via inhibition of ZIKV NS5 polymerase activity and disruption of lysosomal function. In the present study, our preliminary result indicated that emetine inhibited MERS-CoV entry. Interestingly, the immunosuppressant mycophenolic acid and its derivative mycophenolate mofetil, which suppress MERS-CoV replication (33) , also inhibited HCoV-OC43 replication (EC 50 values of 1.95 and 1.58 M, respectively). However, a previous study showed that MERS-CoV-infected common marmosets treated with mycophenolate mofetil had more severe forms of disease and higher lung viral loads than did untreated animals, and renal transplant recipients on maintenance mycophenolate mofetil therapy reportedly developed severe or fatal MERS (60) . Therefore, these two inhibitors are unlikely to be useful against CoV infections. Monensin sodium, which affects IBV and MHV-A59 assembly (61, 62) , was also identified as an inhibitor of other CoVs (MERS-CoV, HCoV-OC43, and HCov-NL63) in this study.

Lycorine showed strong antiviral activity against multiple genetically distinct CoVs in vitro and protected mice against lethal HCoV-OC43 infection in vivo. To our knowledge, this is the first report of the use of BLI to evaluate the effects of antiviral agents on CoV replication and dissemination in vivo without the need for sacrificing animals to quantify viral titers and establish the complete pattern of virus dissemination in the central nervous system. However, most of the data and conclusions concerning the antiviral effects of the inhibitors were derived only from one cell line and should be tested in different CoV replication cell lines in order to exclude the influence of host cell factors, especially for MERS-CoV, for which there are a larger number of susceptible cell lines (e.g., Huh 7 or Calu3/2B4 cells). Therefore, further in vitro and in vivo studies are warranted to determine the potential antiviral mechanisms associated with the seven compounds, as well as their clinical efficacy. Additionally, the efficacy of lycorineinterferon combinations should be explored in animal models.

Following SARS and MERS, future emerging CoVs will likely pose a threat to public health. Therefore, identification of broad-spectrum inhibitors of SARS-CoV, MERS-CoV, and future emerging CoVs is a research priority. From this perspective, the potent broad-spectrum inhibitors (lycorine and emetine) identified in this study might be effective against CoV infections either as single agents or in combination.

Cell lines, viruses, compounds, and antibodies. BHK-21, Vero-E6, LLC-MK2, DBT, 293FT, DPP4expressing Huh7.5 cells, and 17Cl-1 cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Gibco) and incubated at 37°C in an atmosphere containing 5% CO 2 .

HCoV-OC43 (GenBank accession number AY391777.1) expressing the Rluc gene (rOC43-ns2Del-Rluc) and derived from an infectious cDNA clone (17) was used for HTS in HBK-21 cells. HCoV-NL63 strain Amsterdam I was used to infect monolayers of LLC-MK2 cells at an MOI of 0.01. The MERS-CoV strain EMC was used to infect monolayers of Vero-E6 cells at an MOI of 0.01. The MHV strain A59 was propagated in 17Cl-1 cells, and a plaque assay was performed in monolayers of DBT cells infected with MHV at an MOI of 0.01. A 2,000-compound library containing FDA-approved drugs and pharmacologically active compounds was purchased from MicroSource Discovery Systems, Inc. (Gaylordsville, CT, USA) (see Table S1 in the supplemental material).

The anti-HCoV-OC43 nucleocapsid protein mouse monoclonal antibody was made in-house. Anti-␤-actin (13E5) rabbit monoclonal antibody was obtained from Cell Signaling Technology (Danvers, MA, USA). Infrared IRDye 800CW-labeled goat anti-mouse IgG and 680RD-labeled goat anti-rabbit IgG were purchased from LI-COR Biosciences (Lincoln, NE, USA). Viral load assays. MHV titers were quantified by a plaque assay, as described previously (63) . Viral genomic RNA from HCoV-OC43, HCoV-NL63, and MERS-CoV was extracted from 50 l of cell culture supernatants using a QIAamp viral RNA minikit (Qiagen, Valencia, CA, USA) and quantified by real-time RT-PCR, as described previously (64, 65) . The primer and probe sequences were as follows: q-OC43-F, Primary screening assay and secondary confirmation assay. HCoV-OC43 can replicate efficiently in BHK-21 cells, with this cell line commonly used for virus isolation or antiviral screening assays. Therefore, the primary screening assay was conducted using 10 M each compound in BHK-21 cells. We observed no difference in the average Rluc signal between mock controls (only reporter virus added) and DMSO controls. The average control (mock or DMSO control) signal was ϳ6.3 ϫ 10 6 luciferase light units, and that for the background (only BHK-21 cells) was ϳ25 luciferase light units.

Briefly, ϳ4,000 BHK-21 cells were seeded on 96-well plates in DMEM supplemented with 10% FBS. After overnight incubation in a 5% CO 2 atmosphere at 37°C, each well contained ϳ10,000 cells. The medium was then replaced with 94 l DMEM supplemented with 3% FBS, and 1 l of each compound (diluted in DMSO) was added to the plates at a final concentration of 10 M (one compound per well) in triplicate. An equal volume of DMSO alone was added to the DMSO control wells (Fig. 1A) . After incubation for 60 min, 5 l of diluted viral suspension was added to each well (MOI ϭ 0.01) for a final total screening volume of 100 l/well. The plates were incubated at 37°C for 72 h, and luciferase activity was determined using the Renilla-Glo luciferase assay system (Promega, Madison, WI, USA) according to the manufacturer's instructions. Antiviral activity was calculated as follows: inhibition of Rluc activity (%) ϭ 100% Ϫ (relative luminescence units of compound-treated cells/relative luminescence units of DMSOtreated control cells). Cytotoxicity was calculated as follows: inhibition of BHK-21 proliferation (%) ϭ 100% Ϫ (cell viability of compound-treated cells/cell viability of DMSO-treated control cells). The EC 50 value and the compound-specific toxicity (CC 50 ) were calculated with GraphPad Prism 5 software (GraphPad, Inc., La Jolla, CA, USA) using the nonlinear regression model. The Z factor, an assessment of the quality of screening assays, was determined, and compounds were considered effective if they reduced Rluc activity by Ն70% and cytotoxicity by Յ80%.

A confirmation assay was performed using HCoV-OC43-WT treated with the compounds at two concentrations (10 and 5 M), and viral RNA load was determined by qRT-PCR. To screen hits with higher potency and narrow the screening scope, a compound was considered effective only if the EC 50 value was Ͻ5 M.

Western blot analysis. BHK-21 cells were lysed by incubation in 0.5% NP-40 buffer for 30 min at 4°C. Lysates were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes, which were blocked with 5% skim milk in PBS for 1 h and incubated with the primary antibody overnight at 4°C. After washing with PBS plus Tween 20 buffer, the membranes were incubated for 1 h with the appropriate secondary antibody and scanned using the Odyssey Infrared imaging system (LI-COR Biosciences).

IFA. BHK-21 cells in 96-well plates were infected with HCoV-OC43-WT (MOI ϭ 0.01) in the presence of 10 M the indicated inhibitors, with chloroquine and DMSO used as the positive and negative controls, respectively. At 72 h postinfection, cells were fixed in 4% formaldehyde, permeabilized in 0.5% Triton X-100, blocked in 5% bovine serum albumin in PBS, and then probed with primary antibodies (anti-HCoV-OC43 nucleocapsid protein) for 1 h at room temperature. The cells were washed three times with PBS and then incubated with fluorescein isothiocyanate-labeled goat anti-mouse IgG (Sigma-Aldrich, St. Louis, MO, USA) at a dilution of 1:100 for 1 h. The cells were then washed and stained with 4,6-diamidino-2-phenylindole (DAPI; Invitrogen, Carlsbad, CA, USA) to detect nuclei. Fluorescence images were obtained and analyzed using a fluorescence microscope (TE2000U; Nikon, Melville, NY, USA) with a video documentation system. Cell viability assay. Cell viability was assessed by a methyl-thiazolyl-tetrazolium (MTT) assay. After 72 h, MTT was added to a final concentration of 0.5 mg/ml, and cells were incubated for 3 h in a humidified 5% CO 2 incubator at 37°C. The plates were then centrifuged (500 ϫ g, 10 min), and the supernatant was removed from each well by aspiration with a micropipette. Subsequently, 100 l of DMSO was added per well, and the plates were gently shaken. The absorbance at 580 nm was detected using a Microelisa Auto Reader MR580 spectrometer (Dynatech Laboratories, Inc., Charlottesville, VA, USA).

MERS-CoV entry inhibition assay. The inhibitory activity of the selected inhibitors on CoV entry was determined using pseudoviruses, as described previously (41) . Briefly, 293FT cells were cotransfected with plasmids PNL4-3.luc.RE-and pVRC-MERS-S, and the culture supernatant containing sufficient pseudotyped MERS-CoV was collected at 72 h posttransfection. Upon reaching a density of 5,000 cells/well in a 96-well plate, dipeptidyl peptidase 4 (DPP4)-expressing Huh7.5 cells were infected with 200 TCID 50 of the pseudovirus MERS-CoV in the presence of each inhibitor at different concentrations. The culture medium was renewed with fresh medium containing 2% FBS, and luciferase activity was determined after an additional 48 h of incubation using a Promega GloMax 96 plate luminometer (Promega).

Mice and infection. Twelve-day-old female BALB/c mice were inoculated via the intranasal route with 100 TCID 50 HCoV-OC43-WT or rOC43-ns2Del-Rluc. After 2 h, the mice were treated with the test compounds in 1ϫ DMSO and PBS buffer. The animals were injected intraperitoneally daily with 10 l of the compounds (emetine was used at 5 mg/kg, chloroquine was used at 30 mg/kg, and other inhibitors were used at 15 mg/kg), and survival was monitored for 20 days postinoculation. All procedures involving animals were performed in compliance with the Guide for the Care and Use of Laboratory Animals of the People's Republic of China. The study protocol was approved by the Committee on the Ethics of Animal Experiments of the Chinese Center for Disease Control and Prevention.

BLI. BALB/c mice were infected with rOC43-ns2Del-Rluc and treated with lycorine or DMSO-PBS, followed by immediate anesthetization with 2% isoflurane and intraperitoneal administration of ViviRen in vivo Renilla luciferase substrate (20 g/g; Promega) at 2, 3, and 4 days postinoculation. The mice were positioned in a specially designed box and placed onto the stage inside the light-tight camera box. Mice were imaged within 5 min postinjection of the substrate, and photon flux was quantitated using Living Image software (PerkinElmer, Waltham, MA, USA).

IHC. Mouse brains were removed at 3 days postinfection and fixed in formalin, and the tissues were processed for IHC, as described previously (66) .

Statistical analysis. Differences between groups were examined for statistical significance using Student's t test. A P of Ͻ0.05 was considered statistically significant.

Supplemental material for this article may be found at https://doi.org/10.1128/JVI .00023-19.

SUPPLEMENTAL FILE 1, XLS file, 0.5 MB.

A planarian nidovirus expands the limits of RNA genome size

Coronavirus diversity, phylogeny and interspecies jumping

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing

Mosaic structure of human coronavirus NL63, one thousand years of evolution

Epidemiology, genetic recombination, and pathogenesis of coronaviruses

SARS and MERS: recent insights into emerging coronaviruses

Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, crosssectional, serological study

Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study

A major outbreak of severe acute respiratory syndrome in Hong Kong

IFN-␣2a or IFN-␤1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study

Clinical features and shortterm outcomes of 144 patients with SARS in the greater Toronto area

Coronaviruses-drug discovery and therapeutic options

Screening of an FDA-approved compound library identifies four smallmolecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture

Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection

Broad-spectrum antiviral activity of the eIF4A inhibitor silvestrol against corona-and picornaviruses

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Safe and sensitive antiviral screening platform based on recombinant human coronavirus OC43 expressing the luciferase reporter gene

1H and 13C NMR analysis of lycorine and ␣-dihydrolycorine

Lycorine hydrochloride inhibits metastatic melanoma cell-dominant vasculogenic mimicry

Antiplasmodial alkaloids from bulbs of Amaryllis belladonna Steud

Antibacterial activity and virtual screening by molecular docking of lycorine from Pancratium foetidum Pom (Moroccan endemic Amaryllidaceae)

Lycorine protects cartilage through suppressing the expression of matrix metalloprotenases in rat chondrocytes and in a mouse osteoarthritis model

The antihelmintic drug pyrvinium pamoate targets aggressive breast cancer

Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice

Vacuolating encephalitis in mice infected by human coronavirus OC43

Human respiratory coronavirus OC43: genetic stability and neuroinvasion

Human coronavirus OC43 associated with fatal encephalitis

Detection of coronavirus in the central nervous system of a child with acute disseminated encephalomyelitis

Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection

Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease

Middle East respiratory syndrome

Inhibition of novel ␤ coronavirus replication by a combination of interferon-␣2b and ribavirin

Interferon-␤ and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays

HIV protease inhibitor nelfinavir inhibits replication of SARSassociated coronavirus

Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus

Saracatinib inhibits Middle East respiratory syndrome-coronavirus replication in vitro

A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective

Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease

Protective effect of intranasal regimens containing peptidic Middle East respiratory syndrome coronavirus fusion inhibitor against MERS-CoV infection

Ultra-potent human neutralizing antibody repertoires against MERS-CoV from a recovered patient

Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein

Lycorine and its derivatives for anticancer drug design

Synthesis and antiplasmodial activity of lycorine derivatives

New lycorine-type alkaloid from Lycoris traubii and evaluation of antitrypanosomal and antimalarial activities of lycorine derivatives

Rapid identification of inhibitors that interfere with poliovirus replication using a cell-based assay

Bunyamwera virus possesses a distinct nucleocapsid protein to facilitate genome encapsidation

Antiviral (RNA) activity of selected Amaryllidaceae isoquinoline constituents and synthesis of related substances

Identification of natural compounds with antiviral activities against SARS-associated coronavirus

Lycorine reduces mortality of human enterovirus 71-infected mice by inhibiting virus replication

A conserved inhibitory mechanism of a lycorine derivative against enterovirus and hepatitis C virus

Amaryllidaceae alkaloids inhibit nuclear-to-cytoplasmic export of ribonucleoprotein (RNP) complex of highly pathogenic avian influenza virus H5N1

Drug repositioning as a route to anti-malarial drug discovery: preliminary investigation of the in vitro anti-malarial efficacy of emetine dihydrochloride hydrate

Antiviral activity of emetine dihydrochloride against dengue virus infection

Natural plant alkaloid (emetine) inhibits HIV-1 replication by interfering with reverse transcriptase activity

Emetine inhibits replication of RNA and DNA viruses without generating drug-resistant virus variants

Retrograde axonal transport of rabies virus is unaffected by interferon treatment but blocked by emetine locally in axons

Efficacy and mechanism of action of low dose emetine against human cytomegalovirus

Emetine inhibits Zika and Ebola virus infections through two molecular mechanisms: inhibiting viral replication and decreasing viral entry

Treatment with lopinavir/ritonavir or interferon-␤1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset

Replication and morphogenesis of avian coronavirus in Vero cells and their inhibition by monensin

Post-translational glycosylation of coronavirus glycoprotein E1: inhibition by monensin

Coronavirus protein processing and RNA synthesis is inhibited by the cysteine proteinase inhibitor e64dd

Characterization of human coronavirus etiology in Chinese adults with acute upper respiratory tract infection by real-time RT-PCR assays

Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections

Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against Middle East respiratory syndrome coronavirus challenge

We thank P. J. Talbot